抗抑郁药曲唑酮治疗40例女性功能性消化不良病人

目的:观察曲唑酮治疗功能性消化不良(FD)的疗效。方法:40例女性FD病人予曲唑酮治疗6 wk(曲唑酮组),另外40例女性FD病人给予安慰剂治疗6 wk(安慰剂组)。用HAMD量表和水负荷试验对治疗前后FD病人和健康对照者(正常对照组)的精神状态和胃功能进行评估。同时对治疗前后病人腹胀、腹痛和早饱症状的缓解情况进行了评估。结果:曲唑酮组和安慰剂组治疗前HAMD评分分别为(23±s 5),(21±5)分,均高于正常对照组(3．8±2．8)分,均P<0．01;曲唑酮组和安慰剂组治疗前水负荷量分别为(918±164), (919±210)mL,均低于正常对照组(1 853±190)mL,均P<0．01;曲唑酮组治疗前后HAMD评分和水负荷量均有非常明显差异,均P<0．01;曲唑酮组和安慰组治疗前的症状积分为(6．5±1．4),(6．4±1．7)分,要明显高于治疗后(3．4±1．9),(5．6±1．7)分(P<0．01);曲唑酮组治疗后症状积分要明显低于安慰剂组(P<0．01);所有FD病人HAMD评分和水负荷量均呈负相关(均P<0．05)。结论:曲唑酮对FD病人的抑郁症状和胃容受性扩张功能都有明显改善,腹胀、腹痛和早饱症状也有一定缓解。

Anti-depression drug trazodone in treating 40 female patients with functional dyspepsia

AIM:To evaluate the role of anti-depression drug trazodone on functional dyspepsia (FD). METHODS: Forty female patients of FD received trazodone treatment for 6 wk (trazodone group) and other 40 received placebo at the same time (placebo group) and some healthy people were served as the control group. Hamilton depression scale (HAMD) and water loading test (WLT) were used to evaluate the psychological conditions and gastric functions of all healthy controls and FD patients before and after the treatment. RESULTS: Both HAMD scores of pre-cure trazodone group (23±s 5) and pre-cure placebo (21±5) were significantly higher than that of healthy control group (3.8±2.8, each P < 0.01). Both WLT quantity of pre-cure trazodone group (918±164) mL and pre-cure placebo group (919±210) mL were significantly lower than that of healthy control group ((1 853±190) mL, each P < 0.01); with a significant difference of HAMD score and WLT quantity between pre-cure trazodone group and post-cure trazodone group (each P < 0.01). The symptom score of pre-cure trazodone group (6.5±1.4) was much higher than that of post-cure trazodone group (3.4±1.9, P < 0.01). For the placebo group, the symptom score of pre-cure (6.4±1.7) was much higher than that of the post-cure (5.6±1.7, P < 0.01). The symptom score of post-cure trazodone group was lower than that of post-cure placebo group (P < 0.01) . All functional dyspepsia patients presented with a negative correlation between HAMD score and WLT quantity (each P < 0.05). CONCLUSION: Trazodone possesses a significant ability in improvement depressive symptoms and gastric accommodation function for FD patients with actually relieve of FD symptoms including bloating, abdominal pain, and early satiety.